HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

[Effect of the class III antiarrhythmic drug nibentan in vagotonic atrial fibrillation].

Abstract
Nibentan, the class III antiarrhythmic drug, was experimentally investigated in anaesthetized dogs using the model of vagotonic atrial fibrillation. Under the conditions of vagus nerve stimulation, nibentan retained the ability to prolong the ventricular repolarization and increase the effective refractory periods and to maintain the frequency-independent action on the effective refractory periods of the atrium. At the same time, nibentan did not affect conduction via the His-Purkinje system and prevented bradycardia induced by vagus stimulation. The drug was found to depress the conduction in atrium, this effect being retained on the background of vagus nerve stimulation. Nibentan has proved to be effective in preventing the vagotonic atrial fibrillation.
AuthorsE P Popova, V V Lyskovtsev, N V Kaverina
JournalEksperimental'naia i klinicheskaia farmakologiia (Eksp Klin Farmakol) 2006 Jan-Feb Vol. 69 Issue 1 Pg. 24-7 ISSN: 0869-2092 [Print] Russia (Federation)
PMID16579055 (Publication Type: Journal Article)
Chemical References
  • Anti-Arrhythmia Agents
  • Benzamides
  • nibentan
Topics
  • Animals
  • Anti-Arrhythmia Agents (therapeutic use)
  • Atrial Fibrillation (drug therapy, physiopathology)
  • Benzamides (therapeutic use)
  • Disease Models, Animal
  • Dogs
  • Electric Stimulation
  • Electrocardiography
  • Heart Rate (drug effects)
  • Vagotomy
  • Vagus Nerve (physiopathology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: